Multiple FDA-approved kinase inhibitors currently in use for melanoma include a combination of the MEK inhibitor (MEKi) trametinib (GSK1120212) and BRAF inhibitor dabrafenib for BRAFV600 mutations. Here, BRAF is linked to melanoma.